that there is a problem with the on-site management of this company. The dripping leak is not conducive to reducing costs, but also easy to induce safety problems.
Summer is here, big coffees invite you to show off your muscles (chicken) results | Call for entries "Chicken Processing and Research"
Time of Update: 2021-03-30
papers in journals such as Food Chemistry, LWT-Food Science and Technology, Food Control, "Journal of Agricultural Engineering", "Food Science", obtained 8 provincial scientific and technological appraisal achievements, 3 authorized invention
Foods Special Issue Call for Papers | Cutting-edge research on the quality of grain, oil and food processing
Time of Update: 2021-03-30
Aimin ShiGuest EditorInstitute of Food Science and Technology, Chinese Academy of Agricultural Sciences/Key Laboratory of Agro-Products Processing, Ministry of Agriculture and Rural Affairs, Beijing 100193, ChinaEmail: shiaimin@caas.
Global average temperature may rise by 7 degrees Celsius in 2100, scientists call for reduction of carbon emissions
Time of Update: 2021-03-29
, French scientists issued a warning that the greenhouse effect problem was more serious than previously thought. The worst estimate is that by 2100, the global average temperature will increase by 7 degrees Celsius.
AstraZeneca/Mersk’s Lynparza combined with Roche Avastin is recommended in the UK for the treatment of ovarian cancer
Time of Update: 2021-03-27
The US FDA approved the drug for use in advanced ovarian cancer with germline BRCA mutation (gBRCAm) that has received three or more chemotherapies.
AstraZeneca's CLL drug Calquence is approved by NICE in the UK
Time of Update: 2021-03-27
CompilationFan DongdongA few days ago, the National Institute of Health and Clinical Optimization (NICE) decided to recommend AstraZeneca’s BTK inhibitor Calquence (Acalabrutinib) into the British National Health Service (NHS) for the treatment of certain adult chronic lymphocytic leukemia (CLL).
Summer is here, big coffees invite you to show off your muscles (chicken) results | Call for entries "Chicken Processing and Research"
Time of Update: 2021-03-26
papers in journals such as Food Chemistry, LWT-Food Science and Technology, Food Control, "Journal of Agricultural Engineering", "Food Science", obtained 8 provincial scientific and technological appraisal achievements, 3 authorized invention
Foods Special Issue Call for Papers | Cutting-edge research on the quality of grain, oil and food processing
Time of Update: 2021-03-26
Aimin ShiGuest EditorInstitute of Food Science and Technology, Chinese Academy of Agricultural Sciences/Key Laboratory of Agro-Products Processing, Ministry of Agriculture and Rural Affairs, Beijing 100193, ChinaEmail: shiaimin@caas.
Ao Hushan: Call on all people to learn cardiopulmonary resuscitation techniques and set up "National First Aid Day"
Time of Update: 2021-03-25
According to Ao Hushan, taking Shenzhen as an example, a total of 5,000 AEDs have been deployed in the past three years, and 23 patients have been successfully rescued, benefiting 23 families.
National centralized drug procurement inventory-dare to call the market a new day
Time of Update: 2021-03-24
544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:2em;box-sizing:border-box !important;'> 544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:2em;box-sizing:border-box !important;'> The average price drop in the four rounds of centralized procurement increased from 4+7 to 51% to 75% in the fourth round of bid opening, with a median of 77%.
The world's most expensive drug Novartis SMA gene therapy Zolgensma is included in UK health insurance
Time of Update: 2021-03-22
According to the latest news, Novartis spinal muscular atrophy (SMA) gene therapy Zolgensma (onasemnogene abeparvovec) has been approved to be included in the British National Health Service (NHS).
Eli Lilly's RET inhibitor Retsevmo is approved in the UK for the treatment of advanced lung/thyroid cancer
Time of Update: 2021-03-21
In particular, the authorization includes Restevmo (Selpercatinib) as the only treatment option for patients with advanced RET fusion-positive non-small cell lung cancer (NSCLC) who require systemic treatment before receiving immunotherapy and/or platinum-based chemotherapy.
